Search and analyze individual stocks with comprehensive metrics

Alpa Laboratories Ltd

ALPAPharmaceuticals
68.62+0.00 (+0.00%)
As on 19 Jan 2026, 10:08 amMarket Open

Fundamental Score

...

Alpa Laboratories Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

12.09%
Average

Return on Capital Employed

15.79%
Poor

Operating Profit Margin (5Y)

7.66%
Poor

Dividend Yield

0.00%

Valuation Metrics

Excellent

Price to Earnings

8.59x

Market Capitalization

160.35 (Cr)

Industry P/E

31.77x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-98.57%
Poor

YoY Quarterly Sales Growth

5.29%
Poor

Sales Growth (5Y)

5.24%
Excellent

EPS Growth (5Y)

49.23%
Excellent

Profit Growth (5Y)

49.23%

Financial Health

Excellent

Debt to Equity

0.00x
Excellent

Interest Coverage

121.32x
Good

Free Cash Flow (5Y)

15.17 (Cr)

Ownership Structure

Good

Promoter Holding

57.29%
Poor

FII Holding

0.35%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
57.29%
Promoter Holding
160.35 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of ALPA across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Excellent ROCE Performance (15.79%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Attractive Valuation (P/E: 8.59 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.

Excellent EPS Growth (49.23% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (49.23% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (121.32x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (57.29%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

4 factors identified

Profit Decline Concern (-98.57%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Limited Institutional Interest (FII+DII: 0.35%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Alpa Laboratories Ltd

About ALPA

Business Overview

Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.

Company Details

Symbol:ALPA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mahendra Singh Chawla
Chairman of the Board
Mr. Paresh Chawla
MD & Director
Mr. Bakulesh Chandulal Shah
Chief Financial Officer

ALPA Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)12.09%
Return on Capital Employed15.79%
Operating Profit Margin (5Y)7.66%
Debt to Equity Ratio0.00
Interest Coverage Ratio121.32

Growth & Valuation

Sales Growth (5Y)5.24%
Profit Growth (5Y)49.23%
EPS Growth (5Y)49.23%
YoY Quarterly Profit Growth-98.57%
YoY Quarterly Sales Growth5.29%

Frequently Asked Questions

What is the current price of Alpa Laboratories Ltd (ALPA)?

As of 19 Jan 2026, 10:08 am IST, Alpa Laboratories Ltd (ALPA) is currently trading at ₹68.62. The stock has a market capitalization of ₹160.35 (Cr).

Is ALPA share price Overvalued or Undervalued?

ALPA is currently trading at a P/E ratio of 8.59x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.

What factors affect the Alpa Laboratories Ltd share price?

Key factors influencing ALPA's price include its quarterly earnings growth (Sales Growth: 5.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Alpa Laboratories Ltd a good stock for long-term investment?

Alpa Laboratories Ltd shows a 5-year Profit Growth of 49.23% and an ROE of 12.09%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.

How does Alpa Laboratories Ltd compare with its industry peers?

Alpa Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ALPA's P/E of 8.59x and ROE of 12.09% against the industry averages to determine its competitive standing.

What is the P/E ratio of ALPA and what does it mean?

ALPA has a P/E ratio of 8.59x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹9 for every ₹1 of annual earnings.

How is ALPA performing according to Bull Run's analysis?

ALPA has a Bull Run fundamental score of 55.7/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does ALPA belong to?

ALPA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alpa Laboratories Ltd.

What is Return on Equity (ROE) and why is it important for ALPA?

ALPA has an ROE of 12.09%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Alpa Laboratories Ltd generates profits from shareholders' equity.

How is ALPA's debt-to-equity ratio and what does it indicate?

ALPA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is ALPA's dividend yield and is it a good dividend stock?

ALPA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has ALPA grown over the past 5 years?

ALPA has achieved 5-year growth rates of: Sales Growth 5.24%, Profit Growth 49.23%, and EPS Growth 49.23%.

What is the promoter holding in ALPA and why does it matter?

Promoters hold 57.29% of ALPA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is ALPA's market capitalization category?

ALPA has a market capitalization of ₹160 crores, placing it in the Small-cap category.

How volatile is ALPA stock?

ALPA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for ALPA?

ALPA has a 52-week high of ₹N/A and low of ₹N/A.

What is ALPA's operating profit margin trend?

ALPA has a 5-year average Operating Profit Margin (OPM) of 7.66%, indicating the company's operational efficiency.

How is ALPA's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 5.29% and YoY Profit Growth of -98.57%.

What is the institutional holding pattern in ALPA?

ALPA has FII holding of 0.35% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.